Clinical trials
Pancreatitis clinical trials
Below are recruiting pancreatitis clinical trials, each written for real people, not researchers. We’re tracking 1,040 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT06397846Recruiting
Blood markers for benign vs. malignant pancreas changes
This study looks for markers in the body that can tell the difference between harmless (benign) and dangerous (malignant) pancreatic growths. It may help doctors learn more about changes in the pancreas and guide better care.
BesançonAges 18 years+ - NCT06246630Recruiting
Personalized drug testing for advanced pancreatic neuroendocrine tumors
This trial uses a lab-grown model of your tumor (called an organoid) to test which drugs might work best for you. It is for people with advanced pancreatic neuroendocrine tumors who cannot have surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06149689RecruitingPhase 2
Chemo plus radiation for advanced pancreatic cancer with normal CA19-9
This trial tests whether giving a strong chemotherapy combination (mFOLFIRINOX) together with radiation therapy can help people with advanced pancreatic cancer who have normal CA19-9 levels. It aims to see if this approach is more effective for this specific group of patients.
ShanghaiAges 18–80 - NCT05919238RecruitingPhase 1
Padeliporfin treatment for non-removable pancreatic cancer
This Phase 1 study tests a new cancer treatment called padeliporfin given through a special catheter to treat pancreatic ductal adenocarcinoma that cannot be removed by surgery. It aims to see how safe the treatment is and whether it can help control the tumor in people who are not surgical candidates.
Duarte, CaliforniaAges 18 years+ - NCT05424159Recruiting
Carbon ion radiation for locally advanced pancreatic cancer
This trial tests a type of radiation that uses carbon ions to treat pancreatic cancer that can’t be removed with surgery but has not spread to distant organs. It may help shrink or control the tumor while limiting radiation side effects to nearby organs.
ShanghaiAges 18–80 - NCT04055571Recruiting
Review of pancreatic disease treatments since 2005
This study looks back at people diagnosed with pancreatic disease and how their treatment outcomes turned out. It may help doctors improve care for both non-cancerous and cancerous pancreatic problems.
Richardson, TexasAges 18 years+ - NCT07032974Recruiting
Comparing biopsy needles for pancreatic masses
This trial compares three different types of needles used during an endoscopic ultrasound to see which one gets the best tissue sample for diagnosing a solid pancreatic mass. It may help you if you need a tissue sample of your pancreas.
Bangkok, BangkokAges 18 years+ - NCT06904378RecruitingPhase 1/Phase 2
New drug combo for advanced pancreatic cancer
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
St Louis, MissouriAges 18 years+ - NCT06842303Recruiting
Using new MRI scans to measure pancreatic tumor response
This study tests whether new MRI techniques can better show how pancreatic cancer responds to treatment. It compares standard CT scans with advanced MRI sequences for patients whose cancer has not spread.
Vandœuvre-lès-Nancy, FranceAges 18 years+ - NCT06752811RecruitingPhase 3
Testing a new paclitaxel formula for advanced pancreatic cancer
This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.
Nanjing, JiangsuAges 18–75 - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT06666803Recruiting
Personalized profile of pancreatic tumors from biopsy samples
This study will take a close-up look at your pancreatic tumor by using a sample from a biopsy to create a personal profile. The goal is to understand your cancer better and maybe find the best treatment for you.
StrasbourgAges 18 years+ - NCT06659705RecruitingPhase 2
New PET scan for early pancreatic cancer detection
This trial tests a new type of PET scan that uses a special tracer (FAPI) to get clearer images of pancreatic cancer. The goal is to find cancer earlier and better plan surgery or treatment.
Saint-CloudAges 18 years+ - NCT06576115RecruitingPhase 2
Combination therapy with device for metastatic pancreatic cancer
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
Clarkston, MichiganAges 18 years+ - NCT06182072RecruitingPhase 1
ProAgio for advanced pancreatic cancer
This trial tests a new drug called ProAgio combined with standard chemotherapy for people with stage IV pancreatic cancer. It aims to see if the combination is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT07199764RecruitingPhase 2
Maintenance therapy using combination immunotherapy for pancreatic cancer
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05845801Recruiting
Study registry for young adults with pancreatic cancer
This study is a registry, meaning it collects information about young adults diagnosed with pancreatic cancer. It may help researchers better understand this cancer in younger people and improve future care.
VeronaAges 18–55 - NCT05851924RecruitingPhase 2
Nalirifox plus radiation for nonmetastatic pancreatic cancer
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
Basking Ridge, New JerseyAges 18 years+ - NCT05740111Enrolling by invitation
Watching early for pancreatic cancer in people at high risk
This study tests a personalized “watch and check” plan to help find pancreatic cancer as early as possible in people with a strong family history or certain inherited gene changes. It may help doctors tailor how often you’re monitored based on your risk.
OsloAges 30–80 - NCT05267379Recruiting
Study of causes of pancreatitis after ERCP
This study looks at how genes and medication processing in the body may relate to getting pancreatitis after an ERCP procedure. If you are having an ERCP and meet the criteria, your data and possibly samples may help researchers understand who is at higher risk.
Nijmegen, GelderlandAges 18 years+ - NCT05630989Recruiting
Registry for outcomes in KRAS G12R pancreatic cancer on MEK therapy
This study keeps a registry (a secure database) to track how people with advanced pancreatic cancer and a KRAS G12R mutation do after treatment with a MEK inhibitor–based combination. It helps doctors understand which outcomes matter most for this specific genetic type of cancer.
Milwaukee, WisconsinAges 18 years+ - NCT05243082Recruiting
Ultrasound-guided heating treatment for pancreatic neuroendocrine tumors
This trial tests a procedure that uses an endoscope and ultrasound to heat (radiofrequency ablate) pancreatic neuroendocrine tumors. It may help shrink tumors while aiming to be a less invasive option.
OsloAges 18 years+ - NCT04881487Recruiting
Radiation treatment for local pancreatic cancer recurrence
This trial looks at additional treatment using a special type of focused radiation (stereotactic body radiation therapy) for pancreatic cancer that has come back only in the same area after surgery. It may help by controlling the local recurrence and possibly improving outcomes for people whose cancer has not spread elsewhere.
Amsterdam, North HollandAges 18 years+
Hear when a new Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatitis?
- Yes. Clin2 currently lists 1,040 recruiting pancreatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.